271 related articles for article (PubMed ID: 34051747)
1. Significance of KDM6A mutation in bladder cancer immune escape.
Chen X; Lin X; Pang G; Deng J; Xie Q; Zhang Z
BMC Cancer; 2021 May; 21(1):635. PubMed ID: 34051747
[TBL] [Abstract][Full Text] [Related]
2. EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.
Zhu G; Pei L; Li Y; Gou X
Aging (Albany NY); 2020 Feb; 12(3):2132-2141. PubMed ID: 32012118
[TBL] [Abstract][Full Text] [Related]
3. Profiles of tumor-infiltrating immune cells and prognostic genes associated with the microenvironment of bladder cancer.
Li F; Guo H; Wang Y; Liu B; Zhou H
Int Immunopharmacol; 2020 Aug; 85():106641. PubMed ID: 32470882
[TBL] [Abstract][Full Text] [Related]
4. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
Lv J; Zhu Y; Ji A; Zhang Q; Liao G
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis.
Liu L; Hu J; Wang Y; Sun T; Zhou X; Li X; Ma F
Aging (Albany NY); 2020 Jun; 12(12):11967-11989. PubMed ID: 32570217
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatic Analysis of Immune Significance of RYR2 Mutation in Breast Cancer.
Xu Z; Xiang L; Wang R; Xiong Y; Zhou H; Gu H; Wang J; Peng L
Biomed Res Int; 2021; 2021():8072796. PubMed ID: 34888385
[TBL] [Abstract][Full Text] [Related]
7. X chromosome protects against bladder cancer in females via a
Kaneko S; Li X
Sci Adv; 2018 Jun; 4(6):eaar5598. PubMed ID: 29928692
[TBL] [Abstract][Full Text] [Related]
8. Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.
Nickerson ML; Dancik GM; Im KM; Edwards MG; Turan S; Brown J; Ruiz-Rodriguez C; Owens C; Costello JC; Guo G; Tsang SX; Li Y; Zhou Q; Cai Z; Moore LE; Lucia MS; Dean M; Theodorescu D
Clin Cancer Res; 2014 Sep; 20(18):4935-48. PubMed ID: 25225064
[TBL] [Abstract][Full Text] [Related]
9. Implication of
Matar M; Prince G; Hamati I; Baalbaky M; Fares J; Aoude M; Matar C; Kourie HR
Pharmacogenomics; 2023 Jun; 24(9):509-522. PubMed ID: 37458596
[No Abstract] [Full Text] [Related]
10. Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer.
Cao J; Li J; Yang X; Li P; Yao Z; Han D; Ying L; Wang L; Tian J
Cancer Med; 2021 Aug; 10(15):5375-5391. PubMed ID: 34165261
[TBL] [Abstract][Full Text] [Related]
11. The Analysis of PTPN6 for Bladder Cancer: An Exploratory Study Based on TCGA.
Shen C; Liu J; Wang J; Yang X; Niu H; Wang Y
Dis Markers; 2020; 2020():4312629. PubMed ID: 32454905
[No Abstract] [Full Text] [Related]
12. Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.
Chen X; Yang Z; Feng J; Duan T; Pan T; Yan L; Jin T; Xiang Y; Zhang M; Chen P; Wang W; Zhang R; Chen B; Zhao L; Xie T; Sui X
Cancer Med; 2021 Jan; 10(1):317-324. PubMed ID: 33174323
[TBL] [Abstract][Full Text] [Related]
13.
Kobatake K; Ikeda KI; Nakata Y; Yamasaki N; Ueda T; Kanai A; Sentani K; Sera Y; Hayashi T; Koizumi M; Miyakawa Y; Inaba T; Sotomaru Y; Kaminuma O; Ichinohe T; Honda ZI; Yasui W; Horie S; Black PC; Matsubara A; Honda H
Clin Cancer Res; 2020 Apr; 26(8):2065-2079. PubMed ID: 32047002
[TBL] [Abstract][Full Text] [Related]
14. Tumor‑infiltrating M2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer.
Xue Y; Tong L; LiuAnwei Liu F; Liu A; Zeng S; Xiong Q; Yang Z; He X; Sun Y; Xu C
Oncol Rep; 2019 Aug; 42(2):581-594. PubMed ID: 31233191
[TBL] [Abstract][Full Text] [Related]
15. Differential Occupancy and Regulatory Interactions of KDM6A in Bladder Cell Lines.
Özden-Yılmaz G; Savas B; Bursalı A; Eray A; Arıbaş A; Senturk S; Karaca E; Karakülah G; Erkek-Ozhan S
Cells; 2023 Mar; 12(6):. PubMed ID: 36980177
[TBL] [Abstract][Full Text] [Related]
16. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
Ler LD; Ghosh S; Chai X; Thike AA; Heng HL; Siew EY; Dey S; Koh LK; Lim JQ; Lim WK; Myint SS; Loh JL; Ong P; Sam XX; Huang D; Lim T; Tan PH; Nagarajan S; Cheng CW; Ho H; Ng LG; Yuen J; Lin PH; Chuang CK; Chang YH; Weng WH; Rozen SG; Tan P; Creasy CL; Pang ST; McCabe MT; Poon SL; Teh BT
Sci Transl Med; 2017 Feb; 9(378):. PubMed ID: 28228601
[TBL] [Abstract][Full Text] [Related]
17. Identification of a Prognosis-Related Risk Signature for Bladder Cancer to Predict Survival and Immune Landscapes.
Wang L; Wang Y; Wang J; Li L; Bi J
J Immunol Res; 2021; 2021():3236384. PubMed ID: 34708131
[TBL] [Abstract][Full Text] [Related]
18. Development of a prognostic index and screening of prognosis related genes based on an immunogenomic landscape analysis of bladder cancer.
Qu G; Liu Z; Yang G; Xu Y; Xiang M; Tang C
Aging (Albany NY); 2021 Apr; 13(8):12099-12112. PubMed ID: 33888644
[TBL] [Abstract][Full Text] [Related]
19. Inherited KDM6A
Feng M; Chai C; Hao X; Lai X; Luo Y; Zhang H; Tang W; Gao N; Pan G; Liu X; Wang Y; Xiong W; Wu Q; Wang J
Oncogene; 2024 Jun; 43(23):1757-1768. PubMed ID: 38622203
[TBL] [Abstract][Full Text] [Related]
20. Loss of UTX/KDM6A and the activation of FGFR3 converge to regulate differentiation gene-expression programs in bladder cancer.
Barrows D; Feng L; Carroll TS; Allis CD
Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25732-25741. PubMed ID: 32989154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
